Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
ATE | Toronto | CAD | Real-time | |
ATE | CBOE Canada | CAD | Real-time |
For the nine months ended 31 December 2021, Antibe Therapeutics Inc revenues decreased from C$6.8M to C$0K. Net loss before extraordinary items increased 6% to C$20M. Revenues reflect Citagenix segment decrease of 60% to C$2.7M, Canada segment decrease of 58% to C$1.3M, United States segment decrease of 66% to C$845K. Higher net loss reflects Stock-based Compensation in SGA increase of 76% to C$3.1M (expense).
Period Ending: | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
---|---|---|---|---|
Total Revenue | 0 | 0 | 0 | 2.95 |
Gross Profit | 1.08 | 1.04 | ||
Operating Income | -5.23 | -8.39 | -6.45 | -5.96 |
Net Income | -4.85 | -8.68 | -6.3 | -5.97 |
Period Ending: | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
---|---|---|---|---|
Total Assets | 92.47 | 95.86 | 102.86 | 81.74 |
Total Liabilities | 31.24 | 31.21 | 31.13 | 31.48 |
Total Equity | 61.22 | 64.64 | 71.73 | 50.26 |
Period Ending: | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
---|---|---|---|---|
Period Length: | 9 Months | 6 Months | 3 Months | 12 Months |
Cash From Operating Activities | -13.15 | -11.31 | -4.94 | -0.1 |
Cash From Investing Activities | -0.24 | -0.24 | -0.21 | -0.26 |
Cash From Financing Activities | 0.01 | 0.05 | -0.04 | 66.16 |
Net Change in Cash | -13.38 | -11.49 | -5.18 | 65.79 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review